Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Adalvo Secures First EU Approval For Victoza Rival

After Liraglutide Nod, Company Also Expects Ozempic Approvals In 2024 And 2025

Jun 19 2024

• By Adam Zamecnik

An image of a semaglutide pen — • Source: Shutterstock

Related Content

Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries

Dec 02 2022

Biocon Strikes Mexican Deal For Liraglutide

May 13 2024

Biocon And Zentiva Hail Milestone Liraglutide Approval In UK

Apr 02 2024

Biocon And Biomm Team Up In Brazil On Ozempic Rival – With Potential Near-Term Launch

Apr 26 2024

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

Apr 24 2024

China’s Regulators Accept Jiuyuan Gene’s Application For Ozempic Biosimilar

Apr 08 2024

Biocon Lines Up Another Liraglutide Deal, This Time In Korea

May 28 2024

Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin

Jan 08 2024

Novo Nordisk Has Its Best Year Ever

Jan 31 2024

Additional Topics

EU Biosimilars Generic Drugs BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window